For New RSV Shots, ‘Vaccine Fatigue’ Could Be One Of The Biggest Barriers
Executive Summary
Pfizer and GSK are expected to gain approval and launch in time for this year’s flu season, but must educate public and physicians
You may also be interested in...
Pfizer Anticipates A 'Bolus Of Revenue' From RSV, Prevnar 20 Launches This Year
Biopharmaceuticals president Angela Hwang said the company is anticipating a strong fourth quarter, driven by the launch of an RSV vaccine and expansion of Prevnar 20 for pediatric use.
FDA Panel Agrees GSK’s RSV Vaccine Is Effective But Wants More Data Before Approval
Advisory committee votes 10-2 that data are adequate to support safety of the vaccine in adults 60 and older, voicing concern about small potential safety signals after co-administration with influenza shot. Several members question rush to market with just one season of data.
Phase III Results Show Moderna Could Challenge In Blockbuster RSV Vaccine Market
Moderna has moved fast to catch up with GSK and Pfizer, but will still be up to a year behind in reaching the market in the burgeoning RSV market.